Jones M M, Seilheimer D K, Pollack M S, Curry M, Crane M M, Rossen R D
Immunology Research Laboratory, Veterans Administration Medical Center, Houston, TX 77030.
Am Rev Respir Dis. 1989 Dec;140(6):1636-9. doi: 10.1164/ajrccm/140.6.1636.
Among patients with cystic fibrosis (CF), those in the subset who develop hypergammaglobulinemia and circulating immune complexes often have relatively severe disease and a decreased likelihood of survival. Because Fc receptors have an important role in the removal of immune complexes and because defective Fc receptor function has been associated with inheritance of the histocompatibility antigens HLA DR2 and HLA DR3, we postulated that HLA DR2 and/or HLA DR3 might be genetic markers for this subset of patients with CF. However, in a group of 20 carefully documented patients with CF, we found no association of HLA DR2 or HLA DR3 with serum immunoglobulin, immune complex levels, or evidence of rapidly progressive disease.
在囊性纤维化(CF)患者中,那些出现高丙种球蛋白血症和循环免疫复合物的亚组患者通常病情相对严重,生存可能性降低。由于Fc受体在清除免疫复合物中起重要作用,且Fc受体功能缺陷与组织相容性抗原HLA DR2和HLA DR3的遗传相关,我们推测HLA DR2和/或HLA DR3可能是这一CF患者亚组的遗传标志物。然而,在一组20例记录详尽的CF患者中,我们发现HLA DR2或HLA DR3与血清免疫球蛋白、免疫复合物水平或快速进展性疾病的证据之间并无关联。